Woodline Partners LP Increases Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Woodline Partners LP lifted its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 806,912 shares of the biotechnology company's stock after purchasing an additional 26,956 shares during the period. Woodline Partners LP owned approximately 2.98% of Arcturus Therapeutics worth $13,693,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ARCT. Vanguard Group Inc. grew its holdings in Arcturus Therapeutics by 6.8% during the 4th quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock worth $28,587,000 after acquiring an additional 107,635 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in Arcturus Therapeutics by 129.7% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock worth $14,409,000 after acquiring an additional 479,482 shares in the last quarter. Geode Capital Management LLC grew its holdings in Arcturus Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock worth $9,421,000 after acquiring an additional 3,186 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Arcturus Therapeutics during the 4th quarter worth approximately $9,312,000. Finally, MPM Bioimpact LLC grew its holdings in Arcturus Therapeutics by 109.5% during the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company's stock worth $7,805,000 after acquiring an additional 240,435 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Analyst Ratings Changes

ARCT has been the subject of several analyst reports. Citigroup reiterated a "buy" rating on shares of Arcturus Therapeutics in a report on Tuesday, May 13th. Wells Fargo & Company lowered their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Finally, Canaccord Genuity Group lowered their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $57.80.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock traded down $0.60 during trading hours on Friday, hitting $12.20. The company had a trading volume of 353,268 shares, compared to its average volume of 451,437. The company's 50-day moving average is $11.37 and its two-hundred day moving average is $14.99. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $45.00. The company has a market cap of $330.88 million, a P/E ratio of -5.50 and a beta of 2.36.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. Sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.